secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2024-06-03T23:59:59+00:00
Accession:  0001437749-24-019074
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra reports positive Phase 2 trial results for KP1077 in idiopathic hypersomnia
--------------------------------------------------------------------------------

- KP1077 well-tolerated at up to 320 mg/day; AEs similar to methylphenidate, mostly mild (insomnia, headache, anxiety).
- ESS decreased ~9 points after 5 weeks; at week 7: ESS -9.4 (QD), -8.8 (BID); IHSS -16.1 QD, -12.3 BID.
- Sleep Inertia VAS decreased 25.9 (QD) and 17.2 (BID); Brain Fog Scale decreased 23.8 (QD) and 22.3 (BID).
- PK data supports nighttime dosing; European Commission granted Orphan Drug Designation for KP1077 in IH.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924019074/0001437749-24-019074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924019074/zvra20240530c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-019074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer